Antibody-Drug Conjugates (ADCs) – Biotherapeutic bullets
Immunotherapies especially targeted towards oncology, based on antibody-drug conjugates (ADCs) have recently been boosted by the US Food and Drug Administration approval of Adcetris to treat Hodgkin’s lymphoma and Kadcyla for metastatic breast cancer.
The emphasis of this article is to provide an overview of the design of ADCs in order to examine their ability to find and kill tumour cells. A particular focus will be on the relationship between the cytotoxic drug, chemical linker and the type of monoclonal antibody (MAb) used to make up the components of the ADC. Furthermore, the article will conclude on a carbon-14 labelled linker strategy for ADCs to be utilised in absorption, distribution, metabolism and excretion (ADME) studies towards regulatory new drug approval requirements.View Resource
Almac API, Chemical Development, Analytical & Solid State Services
Almac Sciences provides integrated services from development to commercial scale of advanced intermediates and Active Pharmaceutical Ingredients (API).
We provide a range of services for small molecules (including highly potent) and peptides. We have a proven track record of saving time and cost through the integration of our services and application of innovative biocatalysis and technology solutions.
We offer a full suite of analytical testing for a range of different product types including small molecules, peptides, biologics, conjugates, potent and controlled substances.
Our vast pool of scientific knowledge can help to overcome the analytical challenges that typically arise during drug development.